Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug may delay return of ovarian cancer

NCT ID NCT03519230

Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called BGB-290 (Pamiparib) as a maintenance treatment for people with recurrent ovarian cancer whose tumors shrank or disappeared after platinum-based chemotherapy. The goal is to see if taking this drug daily can delay the cancer from coming back. The trial involves 224 participants in China and compares the drug to a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

224 people

The number who actually took part.

Started

May 2018

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Histologically diagnosed high-grade serous or endometrioid ovarian cancer (including primary peritoneal and fallopian tube cancer) 2. Completion of ≥2 previous platinum-containing regimens (eg, carboplatin or cisplatin) 3. Complete response (CR) or partial response (PR) achieved with last platinum-based chemotherapy regimen as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 4. Ability to be randomized ≤8 weeks after last dose of platinum Key Exclusion Criteria: 1. Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor 2. Progressive disease (PD) as per CA-125 criteria before randomization 3. Diagnosis of myelodysplastic syndrome (MDS) 4. Known history of intolerance to the excipients of the Pamiparib capsule NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fallopian tube cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

Contacts and locations

Locations

  • Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital

    Hefei, Anhui, 230088, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, 515031, China

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, 400030, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, 150000, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, 430079, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410013, China

  • Jiangxi Maternal and Child Health Hospital

    Nanchang, Jiangxi, 330006, China

  • Jilin Cancer Hospital

    Changchun, Jilin, 130021, China

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, 110042, China

  • Obstetrics and Gynecology Hospital of Fudan University

    Shanghai, Shanghai Municipality, 200011, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, 250000, China

  • Southwest Hospital

    Chongqing, Chongqing Municipality, 400038, China

  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North)

    Guangzhou, Guangdong, 510000, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510120, China

  • The First Hospital of Jilin University

    Changchun, Jilin, 130021, China

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, 116023, China

  • The Tumor Hospital Affiliated to Guangxi Medical University

    Nanning, Guangxi, 530021, China

  • Tianjin Central Hospital of Gynecology Obstetrics

    Tianjin, Tianjin Municipality, 300052, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, 300060, China

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China

  • West China Second University Hospital

    Chengdu, Sichuan, 610101, China

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, 264000, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.